- Home
- BFRG vs THAR Comparison
BFRG vs THAR Comparison
Compare BFRG & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- THAR
- Stock Information
- Founded
- BFRG 2017
- THAR 2017
- Country
- BFRG United States
- THAR United States
- Employees
- BFRG 17
- THAR N/A
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- BFRG Technology
- THAR Health Care
- Exchange
- BFRG Nasdaq
- THAR Nasdaq
- Market Cap
- BFRG 15.4M
- THAR 16.8M
- IPO Year
- BFRG 2023
- THAR 2022
- Fundamental
- Price
- BFRG $1.49
- THAR $3.06
- Analyst Decision
- BFRG
- THAR Strong Buy
- Analyst Count
- BFRG 0
- THAR 1
- Target Price
- BFRG N/A
- THAR $17.00
- AVG Volume (30 Days)
- BFRG 139.3K
- THAR 743.6K
- Earning Date
- BFRG 11-07-2025
- THAR 11-06-2025
- Dividend Yield
- BFRG N/A
- THAR N/A
- EPS Growth
- BFRG N/A
- THAR N/A
- EPS
- BFRG N/A
- THAR N/A
- Revenue
- BFRG $33,257.00
- THAR N/A
- Revenue This Year
- BFRG N/A
- THAR N/A
- Revenue Next Year
- BFRG N/A
- THAR N/A
- P/E Ratio
- BFRG N/A
- THAR N/A
- Revenue Growth
- BFRG N/A
- THAR N/A
- 52 Week Low
- BFRG $1.09
- THAR $0.95
- 52 Week High
- BFRG $4.84
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- BFRG 59.62
- THAR 48.69
- Support Level
- BFRG $1.32
- THAR $2.90
- Resistance Level
- BFRG $1.53
- THAR $3.17
- Average True Range (ATR)
- BFRG 0.10
- THAR 0.32
- MACD
- BFRG 0.01
- THAR -0.01
- Stochastic Oscillator
- BFRG 76.00
- THAR 34.69
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.